Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.4.0.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue:    
Contract research revenue $ 0 $ 57,636
Costs and Expenses:    
Research and development 921,711 1,448,413
General and administrative 1,315,777 1,177,841
Total costs and expenses 2,237,488 2,626,254
Loss from operations (2,237,488) (2,568,618)
Other expense, net (7,122) (1,493)
Net loss $ (2,244,610) $ (2,570,111)
Net loss per share - basic and diluted (in dollars per share) $ (0.04) $ (0.07)
Weighted average common shares outstanding:    
Basic and diluted (in shares) 57,287,955 35,561,911